SUTENT
PreclinicalSmall molecule
PfizerSUTENT is one of 86 small molecule programs targeting Kidney Cancer. It is currently in Preclinical.
3
Indications
11
Total Trials
0
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
86 competitors in Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Sutent
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Fotivda
AAVEO Pharmaceuticals, Inc.
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Zanzalintinib
Merck & Co.Phase 3
Libtayo
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Renal Cell Carcinoma2 trials
Biomarkers1 trial
Urothelial Carcinoma1 trial
5 more indications
Metastatic Melanoma1 trial
Clinical Trial of Sutent to Treat Metastatic Melanoma
Completed·—·Phase 2·NCT00631618·12 enrolled
Gastrointestinal Stromal Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SUTENT. EMBL-EBI & Wellcome Sanger Institute.
- [4]